However, the evidence for the use of DPP-4 inhibitors in patients with type 1 myotonic dystrophy (DM1) is primarily derived from observational studies or indirect inferences, with a lack of prospective randomized controlled trials (RCTs) specifically addressing their efficacy and safety in this population. This evidence concerns the gene DPP4 and myotonic dystrophy type 1.